Antiphospholipid Syndrome: Role of Vascular Endothelial Cells and Implications for Risk Stratification and Targeted Therapeutics

Michel T. Corban, Ali Duarte-Garcia, Robert D. McBane, Eric L. Matteson, Lilach O. Lerman, Amir Lerman

Research output: Contribution to journalReview article

30 Scopus citations

Abstract

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by venous thromboembolism, arterial thrombosis, and obstetric morbidities in the setting of persistently positive levels of antiphospholipid antibodies measured on 2 different occasions 12 weeks apart. Patients with APS are at increased risk for accelerated atherosclerosis, myocardial infarction, stroke, and valvular heart disease. Vascular endothelial cell dysfunction mediated by antiphospholipid antibodies and subsequent complement system activation play a cardinal role in APS pathogenesis. Improved understanding of their pathogenic function could help in the risk stratification of patients with APS and provide new molecular therapeutic targets.

Original languageEnglish (US)
Pages (from-to)2317-2330
Number of pages14
JournalJournal of the American College of Cardiology
Volume69
Issue number18
DOIs
StatePublished - May 9 2017

Keywords

  • antiphospholipid antibodies
  • atherosclerosis
  • epidemiology
  • thrombophilia
  • vascular endothelium
  • warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Antiphospholipid Syndrome: Role of Vascular Endothelial Cells and Implications for Risk Stratification and Targeted Therapeutics'. Together they form a unique fingerprint.

  • Cite this